Clinical Trials Logo

Exposure During Pregnancy clinical trials

View clinical trials related to Exposure During Pregnancy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05803200 Completed - Clinical trials for Exposure During Pregnancy

A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy

Start date: March 15, 2023
Phase:
Study type: Observational

The main aim of this study is to provide further information on the safety profile of HyQvia during pregnancy. This will be done by checking the characteristics of the mother and their babies. They will also be checked for any safety outcomes that will occur when exposed to HyQvia during pregnancy.

NCT ID: NCT04493892 Completed - Breast Cancer Clinical Trials

Hair Care Product Use Among Women Of Color

Start date: March 31, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to reduce use of personal care products that contain endocrine disrupting chemicals among women. For this pilot intervention, the investigators focus on the hair care product class of personal care products, the reduction in use of phthalate-containing Hair Care Products (HCPs) and use among pregnant Women of Color (WOC).

NCT ID: NCT02556775 Completed - Clinical trials for Exposure During Pregnancy

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Start date: December 4, 2015
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry is to acquire safety data (including assessment of anti-rHuPH20 antibodies), regarding the course and outcome of pregnancy in women ever treated with HYQVIA. Development of the fetus/infant at birth and for the first 2 years will also be followed.

NCT ID: NCT01911767 Completed - Multiple Sclerosis Clinical Trials

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Start date: October 30, 2013
Phase:
Study type: Observational [Patient Registry]

The primary objective of the study is to prospectively evaluate pregnancy outcomes in women with multiple sclerosis who were exposed to a Registry-specified Biogen Multiple Sclerosis product during the eligibility window for that product. The Registry-specified Biogen MS products being studied are dimethyl fumarate, and Pegylated human interferon beta-1a. The secondary objective of the study is to prospectively evaluate pregnancy outcomes in women with MS who were unexposed to disease-modifying therapies (DMTs).